company background image
ILX

Ilex Medical TASE:ILX Stock Report

Last Price

₪121.70

Market Cap

₪1.4b

7D

3.9%

1Y

14.7%

Updated

25 Jun, 2022

Data

Company Financials
ILX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends4/6

ILX Stock Overview

Ilex Medical Ltd engages in marketing, selling, and supporting equipment, disposables, and reagents for laboratories and healthcare establishments in Israel and South Africa.

Ilex Medical Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Ilex Medical
Historical stock prices
Current Share Price₪121.70
52 Week High₪170.70
52 Week Low₪98.60
Beta-0.11
1 Month Change-3.64%
3 Month Change-16.13%
1 Year Change14.70%
3 Year Change84.31%
5 Year Change181.32%
Change since IPO3,728.38%

Recent News & Updates

Feb 13
Ilex Medical (TLV:ILX) Could Easily Take On More Debt

Ilex Medical (TLV:ILX) Could Easily Take On More Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Nov 25
The Trend Of High Returns At Ilex Medical (TLV:ILX) Has Us Very Interested

The Trend Of High Returns At Ilex Medical (TLV:ILX) Has Us Very Interested

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...

Shareholder Returns

ILXIL HealthcareIL Market
7D3.9%6.9%4.0%
1Y14.7%-27.5%7.1%

Return vs Industry: ILX exceeded the IL Healthcare industry which returned -27.5% over the past year.

Return vs Market: ILX exceeded the IL Market which returned 7.1% over the past year.

Price Volatility

Is ILX's price volatile compared to industry and market?
ILX volatility
ILX Average Weekly Movement5.4%
Healthcare Industry Average Movement5.4%
Market Average Movement5.6%
10% most volatile stocks in IL Market8.8%
10% least volatile stocks in IL Market3.7%

Stable Share Price: ILX is not significantly more volatile than the rest of IL stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: ILX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1977254Tammy Galilihttps://www.ilexmedical.com

Ilex Medical Ltd engages in marketing, selling, and supporting equipment, disposables, and reagents for laboratories and healthcare establishments in Israel and South Africa. The company offers in vitro diagnostic equipment and reagent systems to hospitals, clinics, and other medical institutions; molecular biology products for cancer screening, retro virus viral load, TB, STDs, and other infectious diseases; and equipment, disposables, and reagents for in vitro fertilization, as well as food and pharma industries. It also distributes and supports nucleic acid testing blood screening solutions to large-scale blood banks; provides pre/post analytics and robotics; and develops, markets, implements, and supports laboratory information systems.

Ilex Medical Fundamentals Summary

How do Ilex Medical's earnings and revenue compare to its market cap?
ILX fundamental statistics
Market Cap₪1.37b
Earnings (TTM)₪202.74m
Revenue (TTM)₪1.03b

6.8x

P/E Ratio

1.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ILX income statement (TTM)
Revenue₪1.03b
Cost of Revenue₪632.05m
Gross Profit₪399.05m
Other Expenses₪196.31m
Earnings₪202.74m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)17.97
Gross Margin38.70%
Net Profit Margin19.66%
Debt/Equity Ratio0.4%

How did ILX perform over the long term?

See historical performance and comparison

Dividends

4.4%

Current Dividend Yield

30%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is ILX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ILX?

Other financial metrics that can be useful for relative valuation.

ILX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.2x
Enterprise Value/EBITDA4.1x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does ILX's PE Ratio compare to its peers?

ILX PE Ratio vs Peers
The above table shows the PE ratio for ILX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average16.1x

Price-To-Earnings vs Peers: ILX is good value based on its Price-To-Earnings Ratio (6.8x) compared to the peer average (16.1x).


Price to Earnings Ratio vs Industry

How does ILX's PE Ratio compare vs other companies in the Healthcare Industry?

Price-To-Earnings vs Industry: ILX is good value based on its Price-To-Earnings Ratio (6.8x) compared to the Asian Healthcare industry average (17.1x)


Price to Earnings Ratio vs Fair Ratio

What is ILX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ILX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ILX's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ILX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ILX (₪121.7) is trading below our estimate of fair value (₪419.24)

Significantly Below Fair Value: ILX is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ILX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Ilex Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


17.4%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ilex Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Ilex Medical is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.

Past Performance

How has Ilex Medical performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


40.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ILX has high quality earnings.

Growing Profit Margin: ILX's current net profit margins (19.7%) are higher than last year (13.8%).


Past Earnings Growth Analysis

Earnings Trend: ILX's earnings have grown significantly by 40.6% per year over the past 5 years.

Accelerating Growth: ILX's earnings growth over the past year (39.1%) is below its 5-year average (40.6% per year).

Earnings vs Industry: ILX earnings growth over the past year (39.1%) exceeded the Healthcare industry 31.2%.


Return on Equity

High ROE: ILX's Return on Equity (35.9%) is considered high.


Discover strong past performing companies

Financial Health

How is Ilex Medical's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ILX's short term assets (₪630.1M) exceed its short term liabilities (₪287.1M).

Long Term Liabilities: ILX's short term assets (₪630.1M) exceed its long term liabilities (₪56.2M).


Debt to Equity History and Analysis

Debt Level: ILX has more cash than its total debt.

Reducing Debt: ILX's debt to equity ratio has reduced from 37% to 0.4% over the past 5 years.

Debt Coverage: ILX's debt is well covered by operating cash flow (10755.2%).

Interest Coverage: ILX's interest payments on its debt are well covered by EBIT (189.3x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Ilex Medical current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


4.37%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: ILX's dividend (4.37%) is higher than the bottom 25% of dividend payers in the IL market (2.06%).

High Dividend: ILX's dividend (4.37%) is low compared to the top 25% of dividend payers in the IL market (6.24%).


Stability and Growth of Payments

Stable Dividend: ILX's dividend payments have been volatile in the past 10 years.

Growing Dividend: ILX's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (29.6%), ILX's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (31.2%), ILX's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Tammy Galili (49 yo)

6.33yrs

Tenure

₪1,917,000

Compensation

Mrs. Tammy Galili has been the Chief Executive Officer of Ilex Medical Ltd since February 14, 2016 and served as its Executive Vice President. She is Director at Kadimastem Ltd since 2022. Mrs. Galili serv...


CEO Compensation Analysis

Compensation vs Market: Tammy's total compensation ($USD560.49K) is about average for companies of similar size in the IL market ($USD719.35K).

Compensation vs Earnings: Tammy's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ILX's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: ILX's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ilex Medical Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Ilex Medical Ltd
  • Ticker: ILX
  • Exchange: TASE
  • Founded: 1977
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Implied Market Cap: ₪1.373b
  • Shares outstanding: 11.28m
  • Website: https://www.ilexmedical.com

Number of Employees


Location

  • Ilex Medical Ltd
  • Kodak Building
  • 7 Hatnufa Street
  • Petah Tikva
  • 4951025
  • Israel

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/25 00:00
End of Day Share Price2022/06/23 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.